1
Expert Opinion
Investing in the Impact Generation - Part #6
Bill Davis
|
Investing in the Impact Generation
Welcome to MutualFunds.com
Please help us personalize your experience and select the one that best describes you.
Your personalized experience is almost ready.
Thank you!
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission
We hope you enjoy your experience
Fixed income news, reports, video and more.
Municipal bonds news, reports, video and more.
Practice management news, reports, video and more.
Portfolio management news, reports, video and more.
Retirement news, reports, video and more.
Learn from industry thought leaders and expert market participants.
Find the latest content and information here about the 2019 Charles Schwab Impact Conference.
18 Most Popular Mutual Fund Categories
View All Categories
15 Most Popular Fund Company Quick Screens
View All Fund Company Quick Screens
Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.
Content focused on helping financial advisors build successful client relationships and grow their business.
Content geared towards helping financial advisors build better client portfolios.
Get insights on the industry trends and investment news from leading fund managers and experts.
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
| Ticker | Mutual Fund | Exposure | % of Shares Owned |
|---|---|---|---|
| FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
| SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
| FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Expert Opinion
Bill Davis
|
Investing in the Impact Generation
Expert Opinion
Bill Davis
|
Investing in the Impact Generation
News
Iuri Struta
|
Global markets were largely down these past two weeks, with small-caps, high-yield bonds...
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Mutual Fund Education
Sam Bourgi
|
The article explores the implications of negative yields and what it might mean...
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
| Ticker | Mutual Fund | Exposure | % of Shares Owned |
|---|---|---|---|
| FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
| SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
| FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Expert Opinion
Bill Davis
|
Investing in the Impact Generation
Expert Opinion
Bill Davis
|
Investing in the Impact Generation
News
Iuri Struta
|
Global markets were largely down these past two weeks, with small-caps, high-yield bonds...
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Mutual Fund Education
Sam Bourgi
|
The article explores the implications of negative yields and what it might mean...
TAXATION
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
MUTUAL FUND EDUCATION
Many investors assume that changes in a mutual fund’s net asset value (NAV)...
MUTUAL FUND EDUCATION
For investors looking to add mutual funds to their portfolio, they need to...
Receive email updates about best performers, news, CE accredited webcasts and more.
Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.